Page last updated: 2024-10-14

pardoprunox

Description

pardoprunox: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918525
CHEMBL ID2103832
SCHEMBL ID805311
MeSH IDM0550671

Synonyms (43)

Synonym
du-126891
7-(4-methylpiperazin-1-yl)-3h-benzooxazol-2-one
L001636
D09397
pardoprunox (usan/inn)
7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one
269718-84-5
5r72chp32s ,
du 126891
2(3h)-benzoxazolone, 7-(4-methyl-1-piperazinyl)-
unii-5r72chp32s
slv 308
7-(4-methylpiperazin-1-yl)-1,3-benzoxazol-2(3h)-one
pardoprunox [usan:inn]
pardoprunox
CHEMBL2103832
slv308
pardoprunox [inn]
du126891
pardoprunox [who-dd]
pardoprunox [usan]
YVPUUUDAZYFFQT-UHFFFAOYSA-N
SCHEMBL805311
CS-4378
7-(4-methyl-1-piperazinyl)-2(3h)-benzoxazolone
7-[(4-methyl)-1-piperazinyl]-2(3h)-benzoxazolone
HY-14958
J-690276
AKOS026750201
EX-A624
pardoprunox (slv308)
DB12061
FT-0700276
BCP17731
Q27882143
pardoprunox free base
269718-84-5 (free base)
F17400
mfcd19443755
slv-308;du-126891
7-(4-methylpiperazin-1-yl)benzo[d]oxazol-2(3h)-one
DTXSID40949747
AC-36807

Compound-Compound Interactions

ExcerptReference
" However, once dyskinesia has developed, dopamine agonists administered with l-dopa exacerbate involuntary movements."( The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Jackson, MJ; Jenner, P; McCreary, AC; Rose, S; Tayarani-Binazir, K, 2010
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's8 (72.73)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (45.45%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (45.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]